Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fed Conditions

NCT01827878 | Completed Phase 1 DMC

• 1 other identifier: Ipca/ARL/10/387
• Study Type: interventional
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

This is a randomized, open Label, balanced, two-treatment, two-period, two-sequence, single dose, cross over pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fed condition in normal, healthy, adult, human subjects.

Conditions

Fed

Outcome Measures

Primary Outcomes (1)

• Bioequivalence is based on Cmax and AUC parameters.

  Sampling Hours: Pre-dose and at 00.50, 01.00, 01.50, 02.00, 02.50, 03.00, 03.50, 04.00, 04.50, 05.00, 05.50, 06.00, 06.50, 07.00, 07.50, 08.00, 09.00, 10.00, 12.00, 16.00, 24.00, 36.00, 48.00 and 72.00 hours post-dose

  5 Months

Study Arms (2)

Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets

ACTIVE COMPARATOR

Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets of M/s AstraZeneca Pharmaceuticals LP, USA

Drug: Lisinopril and Hydrochlorothiazide Tablets (20+25) mg; Drug: Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets

Lisinopril and Hydrochlorothiazide Tablets (20+25) mg

EXPERIMENTAL

Lisinopril and Hydrochlorothiazide Tablets (20+25) mg of M/s Ipca Laboratories Ltd., India

Drug: Lisinopril and Hydrochlorothiazide Tablets (20+25) mg; Drug: Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets

Interventions

Lisinopril and Hydrochlorothiazide Tablets (20+25) mg DRUG

Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day

Also known as: Test product

Lisinopril and Hydrochlorothiazide Tablets (20+25) mg; Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets

Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets DRUG

Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day

Also known as: Reference product

Lisinopril and Hydrochlorothiazide Tablets (20+25) mg; Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male and non-pregnant female human subjects, age in the range of 18 - 45 years (both inclusive).
• Subject willing to give written informed consent.
• Body weight within ± 15% of ideal weight as related to height and body frame according to Life Insurance Corporation (LIC) Chart.
• Subjects with normal findings as determined by baseline history, physical examination and vital signs (blood pressure, pulse rate, respiration rate and oral temperature).
• Subjects with clinically acceptable findings as determined by haemogram, biochemistry including serum electrolytes test, serology (HIV, Hepatitis B and Hepatitis C), urinalysis, 12 lead ECG and chest X-ray (chest X-ray if taken).
• Willingness to follow the protocol requirements as evidenced by written informed consent.
• Confirming and agreeing to, not using any prescription and over the counter medications including vitamins and minerals for 14 days prior to study \& during the course of the study.
• No history of drug abuse in the past one year.
• Non-smokers and Non-alcoholics.
• For female subject:
• Was child bearing potential practicing acceptable method of birth control for the duration of the study as judged by Investigator such as Condom, Foams, Jellies, Diagpharm , Intrauterine device and Abstinence. OR Was surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy has been performed on the subject).

You may not qualify if:

• Known history of hypersensitivity to Lisinopril and Hydrochlorothiazide, other sulfonamide-derived drugs or related drugs.
• Requiring medication for any ailment having enzyme-modifying activity in the previous 28 days, prior to dosing day.
• Any medical or surgical conditions, which might significantly interfere with the functioning of gastrointestinal tract, blood-forming organs etc.
• History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic, hematological, gastrointestinal, endocrine, immunological or psychiatric diseases and bleeding tendency.
• Participation in a clinical drug study or bioequivalence study within 90 days prior to present study.
• History of malignancy or other serious diseases.
• Refusal to abstain from food from at least ten (10.00) hours prior to study drug administration until at least four (04.00) hours post-dose, in each study period.
• Any contraindication to blood sampling or difficulty in accessibility of veins.
• Refusal to abstain from fluid from at least 01.00 hour prior to study drug administration until at least 01.00 hour post-dose, in each study period except about 240 mL of water given during administration of study drug.
• Refusal to avoid the use of xanthine-containing food or beverages (chocolates, tea, coffee or cola drinks) or fruit juice/grapefruit juice and any alcoholic products for 48.00 hours prior to dosing until the last blood sample collection of last study period.
• Blood donation within 90 days prior to the commencement of the study.
• Subjects with positive HIV tests or Hepatitis-B or Hepatitis-C tests.
• Found positive in breath alcohol test done before check-in for each study period.
• Found positive in urine test for drug abuse done before check-in for each study period.
• Refusal to abstain from consumption of tobacco products 24.00 hours prior to dosing until the last blood sample collection of last study period.

Sponsors & Collaborators

• IPCA Laboratories Ltd.: lead

Study Sites (1)

Accutest Research Lab (I) Pvt. Ltd.

Ahmedabad, Gujarat, 380059, India

Location

MeSH Terms

Conditions

Lecithin Cholesterol Acyltransferase Deficiency

Interventions

Lisinopril; Hydrochlorothiazide

Condition Hierarchy (Ancestors)

Hypoalphalipoproteinemias; Hypolipoproteinemias; Lipid Metabolism, Inborn Errors; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Dyslipidemias; Lipid Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Dipeptides; Oligopeptides; Peptides; Amino Acids, Peptides, and Proteins; Chlorothiazide; Benzothiadiazines; Sulfonamides; Sulfones; Sulfur Compounds; Organic Chemicals; Thiazides; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Officials

• Dr. Tarang Girishbhai Shah, M. D. (Pharmacology)

  Accutest Research Lab (I) Pvt. Ltd.

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 5, 2013
• First Posted: April 10, 2013
• Study Start: October 1, 2012
• Primary Completion: October 1, 2012
• Study Completion: October 1, 2012
• Last Updated: April 10, 2013

Record last verified: 2013-04

Locations

IN (1)